The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 13, 2019

Filed:

May. 10, 2018
Applicant:

Immunomet Therapeutics Inc., Houston, TX (US);

Inventors:

Sung Wuk Kim, Gyeonggi-do, KR;

Sung Soo Jun, Gyeonggi-do, KR;

Chang Hee Min, Seoul, KR;

Young Woong Kim, Daejeon, KR;

Min Seok Kang, Gyeonggi-do, KR;

Byung Kyu Oh, Daejeon, KR;

Se Hwan Park, Daejeon, KR;

Yong Eun Kim, Daejeon, KR;

Duck Kim, Daegu, KR;

Ji Sun Lee, Daejeon, KR;

Ju Hoon Oh, Gangwon-do, KR;

Assignee:

ImmunoMet Therapeutics Inc., Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/155 (2006.01); A61K 31/341 (2006.01); A61K 31/472 (2006.01); C07C 277/04 (2006.01); C07C 279/04 (2006.01); C07C 279/06 (2006.01); C07C 279/08 (2006.01); C07C 279/16 (2006.01); C07C 279/18 (2006.01); C07C 279/26 (2006.01); C07D 213/38 (2006.01); C07D 307/52 (2006.01); C07D 317/58 (2006.01); C07D 333/20 (2006.01); A61K 31/4406 (2006.01);
U.S. Cl.
CPC ...
A61K 31/155 (2013.01); A61K 31/341 (2013.01); A61K 31/4406 (2013.01); A61K 31/472 (2013.01); C07C 277/04 (2013.01); C07C 279/04 (2013.01); C07C 279/06 (2013.01); C07C 279/08 (2013.01); C07C 279/16 (2013.01); C07C 279/18 (2013.01); C07C 279/26 (2013.01); C07D 213/38 (2013.01); C07D 307/52 (2013.01); C07D 317/58 (2013.01); C07D 333/20 (2013.01); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2601/18 (2017.05); C07C 2603/74 (2017.05);
Abstract

A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.


Find Patent Forward Citations

Loading…